PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

OncoImmunology

Volumn 5, Issue 12, 2016, Pages

  Jelinek, T ^a,b,c   Hajek, R ^b  

^a UNIVERSITY OF OSTRAVA   (Czech Republic)

^b UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Daratumumab; durvalumab; ibrutinib; irradiation; multiple myeloma; nivolumab; PD 1; PD L1; pembrolizumab; pidilizumab

Indexed keywords

B7 ANTIGEN; CD137 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DARATUMUMAB; DEXAMETHASONE; DURVALUMAB; ELOTUZUMAB; IBRUTINIB; IPILIMUMAB; LENALIDOMIDE; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; POMALIDOMIDE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY TEST; HLA SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LOW DRUG DOSE; MULTIPLE MYELOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SURVIVAL RATE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 85007452270     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1254856     Document Type: Review

References (55)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046-60; PMID:21410373; http://dx.doi.org/10.1056/NEJMra1011442
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
3. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, et al. Continued improvement in survival in multiple myeloma:changes in early mortality and outcomes in older patients. Leukemia 2014; 28:1122-8; PMID:24157580; http://dx.doi.org/10.1038/leu.2013.313
4. San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003):a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14:1055-66; PMID:24007748; http://dx.doi.org/10.1016/S1470-2045(13)70380-2
5. San-Miguel JF, Hungria VTM, Yoon S-S, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma:a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014; 15:1195-206; PMID:25242045; http://dx.doi.org/10.1016/S1470-2045(14)70440-1
6. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 374:1621-34; PMID:27119237; http://dx.doi.org/10.1056/NEJMoa1516282
7. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, et al. Targeting CD38 with Daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373:1207-19; PMID:26308596; http://dx.doi.org/10.1056/NEJMoa1506348
8. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos M-V, Magen H, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373:621-31; PMID:26035255; http://dx.doi.org/10.1056/NEJMoa1505654
9. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372:142-52; PMID:25482145; http://dx.doi.org/10.1056/NEJMoa1411321
10. Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe:trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia 2016; 30(10):2047-54; PMID:27118410; http://dx.doi.org/10.1038/leu.2016.101
11. Ayed AO, Chang L-J, Moreb JS. Immunotherapy for multiple myeloma:Current status and future directions. Crit Rev Oncol Hematol 2015; 96:399-412; PMID:26153389; http://dx.doi.org/10.1016/j.critrevonc.2015.06.006
12. Jelinek T, Hajek R. Monoclonal antibodies - A new era in the treatment of multiple myeloma. Blood Rev 2016; 30:101-10; PMID:26362528; http://dx.doi.org/10.1016/j.blre.2015.08.004
13. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
14. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125:3393-400; PMID:25833961; http://dx.doi.org/10.1182/blood-2015-02-567453
15. Atanackovic D, Luetkens T, Kröger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 2014; 28:993-1000; PMID:24153012; http://dx.doi.org/10.1038/leu.2013.310
16. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331
17. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027
18. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25:9543-53; PMID:16227604; http://dx.doi.org/10.1128/MCB.25.21.9543-9553.2005
19. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81:4215-25; PMID:17287266; http://dx.doi.org/10.1128/JVI.02844-06
20. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-4; PMID:16921384; http://dx.doi.org/10.1038/nature05115
21. Brahmer J, Reckamp KL, Baas P, Crinò, L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373:123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
22. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
23. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373:1803-13; PMID:26406148; http://dx.doi.org/10.1056/NEJMoa1510665
24. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082
25. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.org/10.1056/NEJMoa1411087
26. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, Saudemont A, Quesnel B. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110:296-304; PMID:17363736; http://dx.doi.org/10.1182/blood-2006-10-051482
27. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H, Dong H, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013; 27:464-72; PMID:22828443; http://dx.doi.org/10.1038/leu.2012.213
28. Ray A, Das DS, Song Y, Richardson P, Munshi NC, Chauhan D, Anderson KC. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia 2015; 29:1441-4; PMID:25634684; http://dx.doi.org/10.1038/leu.2015.11
29. Hallett WHD, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 2011; 17:1133-45; PMID:21536144; http://dx.doi.org/10.1016/j.bbmt.2011.03.011
30. Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res 2015; 21:4607-18; PMID:25979485; http://dx.doi.org/10.1158/1078-0432.CCR-15-0200
31. Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, Soni S, Crowley JJ, Orlowski RZ, Barlogie B. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood 2015; 126:2475-8; PMID:26468228; http://dx.doi.org/10.1182/blood-2015-03-632919
32. Paiva B, Azpilikueta A, Puig N, Ocio EM, Sharma R, Oyajobi BO, Labiano S, San-Segundo L, Rodriguez A, Aires-Mejia I, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia 2015; 29:2110-3; PMID:25778100; http://dx.doi.org/10.1038/leu.2015.79
33. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother Hagerstown Md 2011; 34:409-18; PMID:21577144; http://dx.doi.org/10.1097/CJI.0b013e31821ca6ce
34. Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect:a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody. Blood 2010; 116:2286-94; PMID:20460501; http://dx.doi.org/10.1182/blood-2010-02-271874
35. Kearl TJ, Jing W, Gershan JA, Johnson BD. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol Baltim Md 2013; 190:5620-8; PMID:23616570; http://dx.doi.org/10.4049/jimmunol.1202005
36. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy:Preliminary results of a Phase Ib study. J Clin Oncol 2016; 34(23):2698-704; PMID:27269947; http://dx.doi.org/10.1200/JCO.2015.65.9789
37. Mateos M-V, Orlowski RZ, Siegel DS, Reece D, Moreau P, San-Miguel JF. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM):Final efficacy and safety analysis. J Clin Oncol [Internet] 2016 [cited 2016 Jul 25]; Available from:http://meetinglibrary.asco.org/content/167184-176
38. Efebera YA, Rosko A, Hofmeister CC, Benner J, Bakan C, Benson DM. Paper:First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma [Internet]. Orlando, USA 2015 [cited 2016 Jul 25]. Available from:https://ash.confex.com/ash/2015/webprogram/Paper81417.html
39. Rosenblatt J, Avivi I, Binyamini N, Uhl L, Somayia P, Stroopinsky D, Avigan D. Paper:Blockade of PD-1 in combination with dendritic cell/myeloma fusion cell vaccination following autologous stem cell transplantation is well tolerated, induces anti-tumor immunity and may lead to eradication of measureable disease [Internet]. Orlando, USA:2015 [cited 2016 Jul 25]. Available from:https://ash.confex.com/ash/2015/webprogram/Paper80695.html
40. Sedlarikova L, Kubiczkova L, Sevcikova S, Hajek R. Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res 2012; 36:1218-24; PMID:22727252; http://dx.doi.org/10.1016/j.leukres.2012.05.010
41. Azpilikueta A, Agorreta J, Labiano S, Pérez-Gracia JL, Sánchez-Paulete AR, Aznar MA, Ajona D, Gil-Bazo I, Larrayoz M, Teijeira A, et al. Successful immunotherapy against a transplantable mouse squamous lung carcinoma with anti-pd-1 and anti-cd137 monoclonal antibodies. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2016; 11:524-36; PMID:26845193; http://dx.doi.org/10.1016/j.jtho.2016.01.013
42. Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res Off J Am Assoc Cancer Res 2013; 19:6151-62; PMID:24030703; http://dx.doi.org/10.1158/1078-0432.CCR-13-1189
43. Ishibashi M, Tamura H, Sunakawa M, Kondo-Onodera A, Okuyama N, Hamada Y, Moriya K, Choi I, Tamada K, Inokuchi K. Myeloma drug resistance induced by binding of myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunol Res 2016; 4(9):779-88; PMID:27440711; http://dx.doi.org/10.1158/2326-6066.CIR-15-0296
44. Sagiv-Barfi I, Kohrt HEK, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A 2015; 112:E966-72; PMID:25730880; http://dx.doi.org/10.1073/pnas.1500712112
45. Ngiow SF, McArthur GA, Smyth MJ. Radiotherapy complements immune checkpoint blockade. Cancer Cell 2015; 27:437-8; PMID:25873170; http://dx.doi.org/10.1016/j.ccell.2015.03.015
46. Twyman-Saint\sVictor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520:373-7; PMID:25754329; http://dx.doi.org/10.1038/nature14292
47. Binder DC, Fu Y-X, Weichselbaum RR. Radiotherapy and immune checkpoint blockade:potential interactions and future directions. Trends Mol Med 2015; 21:463-5; PMID:26091823; http://dx.doi.org/10.1016/j.molmed.2015.05.007
48. Spisek R, Dhodapkar MV. Towards a better way to die with chemotherapy:role of heat shock protein exposure on dying tumor cells. Cell Cycle Georget Tex 2007; 6:1962-5; PMID:17721082; http://dx.doi.org/10.4161/cc.6.16.4601
49. Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, Lesokhin AM, Devlin SM, Giralt SA, Young JW. T-cell exhaustion in multiple myeloma relapse after Autotransplant:Optimal timing of immunotherapy. Cancer Immunol Res 2016; 4:61-71; PMID:26464015; http://dx.doi.org/10.1158/2326-6066.CIR-15-0055
50. Shien K, Papadimitrakopoulou VA, Wistuba II. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer Amst Neth 2016; 99:79-87; PMID:27565919; http://dx.doi.org/10.1016/j.lungcan.2016.06.016
51. Champiat S, Ferté, C, Lebel-Binay S, Eggermont A, Soria JC. Exomics and immunogenics:Bridging mutational load and immune checkpoints efficacy. Oncoimmunology 2014; 3:e27817; PMID:24605269; http://dx.doi.org/10.4161/onci.27817
52. Atanackovic D, Luetkens T, Kröger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 2014; 28:993-1000; PMID:24153012; http://dx.doi.org/10.1038/leu.2013.310
53. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 2013; 25:214-21; PMID:23298609; http://dx.doi.org/10.1016/j.coi.2012.12.003
54. Suen H, Brown R, Yang S, Weatherburn C, Ho PJ, Woodland N, Nassif N, Barbaro P, Bryant C, Hart D, et al. Multiple myeloma causes clonal T cell immunosenescence:Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia [Internet] 2016; 30(8):1716-24; PMID:27102208; http://dx.doi.org/10.1038/leu.2016.84
55. Dimopoulos MA, Oriol A, Nahi H, San Miguel JF, Bahlis NJ, Moreau P. AN open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (drd) versus lenalidomide and dexamethasone (rd) in relapsed or refractory multiple myeloma (rrmm):pollux [internet]. Vienna, Austria:2016 [cited 2016 Jul 27]. Available from:http://learningcenter.ehaweb.org/eha/2016/21st/135349/meletios.a.dimopoulos.an.open-label.randomised.phase.3.study.of.daratumumab.html?f=m3